Main > A1. CORP. INDEX. V-Vm > Vertex Pharmaceuticals/P C2

---

This data is not available for free

Vertex Pharmaceuticals/P C2's subsections
2000. 10.02.2000. (Targeting DNA)
2001. 11.20.2001. (Comments)
2001. 11.20.2001. (Executive)
2002. 07.29.2002. (Executives)
2002. 10.14.2002. (Subscriber of)
2003. 01.27.2003. (Executive)
2003. 01.27.2003. (IL-1 Inhibitor)
2003. 07.14.2003. (Executive)
2006. 05.30.2006. (Onco/Avalon)
2007. 11.20.2007. (Oncology)
2008. 06.03.2008. HIV Prodt Royalty
2008. 09.01.2008. VP Research
2011. 12.15.2011. CEO
2012. 05.17.2012. CCFC
2012. 05.24.2012. BoD
2012. 06.11.2012. Exec VP & CLO
2012. 09.04.2012. CCO
2012. 09.18.2012. BoD
2012. 09.25.2012. Hepato.>HCV>Als
2012. 10.11.2012. Pneumo.>CF 809
2012. 11.01.2012. Hepato.>HCV GSK
2012. 11.01.2012. Hepato.>HCV J&J
2013. 03.04.2013. Influenza
2013. 04.05.2013. Hepato.>HCV BMS
2013. 04.18.2013. Pneumo.>CF 661
2013. 07.25. Hepato.>HCV>VX-135
2013. 10.18. Rheuma.>RA
2013. 11.20. Hepato.>HCV>Tel
2014. 07.31. Pneumo.>CF>Ivacaftor
2015. 06.04. Parion Sciences
2015. 07.02. Pneumo.>CF>Ivacaftor +
2015. 10.26. CRISPR Therapeutics
2016. 09.28. Pneumo.>CF>Ivacaftor+
2018. 11.01. Pneumo.>CF>Ivacaftor+
2019. 01.03. Arbor Biotechnologies
2019. 01.24. Merck KGaA
2019. 06.06. Duchene Muscular Dystr
2019. 06.21. Pneumo.>CF
2019. 09.03. Acq. Semma Therap.
2019. 10.21. Pneumo.>CF USA>OK
2020. 04.27. Affinia Therapeutics
2020. 08.21. Pneumo.>CF EU>OK
2020. 09.16. Pneumo.>CF>Moderna
2020. 11.27. Pneumo.>CF EU>OK
2020. 12.21. Pneumo.>CF USA>OK
2021. 06.09. Pneumo.>CF USA>OK
2021. 10.26. Mammoth Biosciences
2022. 07.11. Acq. ViaCyte
2022. 09.02. Pneumo.>CF>Ivacaftor+
2023. 04.10. Pneumo.>CF>Ivacaftor+
2023. 04.26. USA FDA Approval
2023. 05.03. USA FDA Approval
2023. 11.16. UK Approval
2023. 11.23. EU Approval
2023. 12.08. Hemato.>SCD>USA>OK
2024. 01.09. Hemato.>SCD>SA>OK
2024. 02.13. Hemato.>SCD>EU>OK
2024. 04.10. Acq. Alpine Immune>
Patents
Web-Site
Z - OK

Vertex Pharmaceuticals/P C2's products
This section has no products